bpc-157 human trial safety clinical data Antinociceptive Effect of in the Formalin-induced Pain Model bpc 157 human clinical trials – FDA panel backs compounded BPC-157,

This rapid inflammation irritates the Trigeminal Nerve

Post-Reconstitution: Once mixed with bacteriostatic water, store in the refrigerator and use within the recommended research timeframe (typically 21-28 days)

What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy

Some users report temporary fatigue or dizziness during the initial stages of treatment